Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case report

Kimimasa Sasaki¹, Shin Kobayashi¹*, Masashi Kudo¹, Motokazu Sugimoto¹, Shinichiro Takahashi¹, Yoshiaki Nakamura², Akihito Kawazoe², Kohei Shitara², Takahiro Kinoshita³ and Naoto Gotohda¹

Abstract

Background: Immune checkpoint inhibitors (ICIs) are emerging agents used for the treatment of various malignant tumors. As ICIs are generally used for unresectable malignant tumors, there have been only a few reports of patients who underwent surgery after receiving these drugs. Therefore, it remains unclear how immune-related adverse events (irAEs) affect the postoperative course. Here, we report a patient with advanced gastric cancer who underwent laparoscopic hepatectomy for liver metastases after an objective response with lenvatinib plus pembrolizumab and developed hypothyroidism and hypopituitarism as irAEs in the immediate postoperative period.

Case presentation: A 73-year-old man had undergone total gastrectomy for pT4aN2M0 gastric cancer followed by adjuvant chemotherapy with S-1 and docetaxel, and developed liver metastases in segments 6 and 7. He was enrolled in phase 2 clinical trial of lenvatinib plus pembrolizumab. He continuously achieved a partial response with the study treatment, and the liver metastases were decreased in size on imaging. The tumors were judged to be resectable and the patient underwent laparoscopic partial hepatectomy for segments 6 and 7. From the 1st postoperative day, the patient continuously presented with fever and general fatigue, and his fasting blood glucose level remained slightly lower than that before the surgery. On the 4th postoperative day, laboratory examination revealed hypothyroidism and hypopituitarism, which were suspected to be irAE caused by lenvatinib plus pembrolizumab after surgery. He received hydrocortisone first, followed by levothyroxine after adrenal insufficiency was recovered. Subsequently, his fever, general fatigue, and any abnormality regarding fasting blood glucose level resolved, and he was discharged on the 12th postoperative day. After discharge, his laboratory data for thyroid and pituitary function remained stable while receiving hydrocortisone and levothyroxine without recurrence of gastric cancer.

*Correspondence: shkobaya@east.ncc.go.jp
1 Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa-City, Chiba 277-8577, Japan
Full list of author information is available at the end of the article
Background
Immune checkpoint inhibitors (ICIs) are emerging agents used for the treatment of various malignant tumors. ICIs are different from conventional anti-cancer drugs in terms of notable side effects called immune-related adverse events (irAEs) such as colitis, hepatitis, and endocrinopathy, which might occur during treatment. As ICIs are generally used for unresectable malignant tumors, there have been only a few reports of patients who underwent surgery after receiving these drugs. Therefore, it remains unclear how irAEs affect the postoperative course.

Recently, a combination of lenvatinib, a small-molecule tyrosine kinase inhibitor, plus pembrolizumab, an anti-programmed death-ligand 1 inhibitor, was shown to have significant antitumor activity with acceptable safety profiles for solid tumors in clinical trials, which led to accelerated approval by the U.S. Food and Drug Administration for the treatment of patients with endometrial cancer with a response rate of 40% [1]. Most recently, we reported promising results of a phase 2 study of lenvatinib plus pembrolizumab for advanced gastric cancer, with a response rate of 69% in the first- or second-line setting [2].

Here, we report a case of advanced gastric cancer who underwent laparoscopic hepatectomy for liver metastases after an objective response with lenvatinib plus pembrolizumab and developed hypothyroidism and hypopituitarism as irAEs in the immediate postoperative period. Because of the retrospective nature of the study and the absence of invasive interventions, patients’ personal written consents were waived.

Case presentation
A 73-year-old man who had undergone total gastrectomy for pathological T4aN2M0 gastric cancer according to UICC-TNM classification 8th edition [3] followed by adjuvant chemotherapy with S-1 and docetaxel for 10 months developed liver metastases 1 year after gastrectomy. The tumors were located in segment 6 (17 mm in diameter) and segment 7 (27 mm in diameter). He was then enrolled in a phase 2 clinical trial of lenvatinib plus pembrolizumab and received the study treatment (20 mg oral lenvatinib once daily and 200 mg intravenous pembrolizumab every 3 weeks) for 5 months [4]. He had grade 2 oral mucositis and proteinuria according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.03) during the study treatment [4]. Thyroid function tests revealed transient hyperthyroidism, which promptly returned to normal. He continuously achieved a partial response with the study treatment, and liver metastases were decreased in size to 8 mm in segments 6 and 11 mm in segment 7 (Fig. 1).

Since the tumors were judged to be systemically under control due to decrease in size of liver metastases and no new lesions by positron emission tomography/computed tomography images, they came to be considered resectable. Four weeks after the last dose of pembrolizumab and 2 weeks after the last dose of lenvatinib, the patient underwent laparoscopic partial hepatectomy for segments 6 and 7. The operation time was 152 min, and blood loss was 109 mL (Fig. 2).

On the 1st postoperative day, his body temperature was elevated to 40.4 °C. The patient complained of general fatigue, which seemed to be unproportional to the physical stress caused by laparoscopic resection of tiny lesions. Fasting blood glucose level remained 80–90 mg/dl, which was slightly lower than that before the surgery. His serum sodium and potassium levels were within the normal ranges. On the 4th postoperative day, laboratory examination for irAE was performed, and prednisolone (100 mg/day) was empirically started for possible adrenal insufficiency. His body temperature and fasting blood glucose levels promptly returned to within a normal range, and general fatigue disappeared. Laboratory data on the 4th postoperative day revealed hypothyroidism (thyroid-stimulating hormone (TSH) 11.56 μU/ml [reference value: 0.50–5.00 μU/ml], Free-T3 0.94 pg/ml [reference value: 2.30–4.30 pg/ml], Free-T4 0.94 ng/dl [reference value: 0.90–1.70 ng/dl]) and hypopituitarism (adrenocorticotropic hormone (ACTH) <1.5 pg/ml [reference value: 7.2–63.3 pg/ml], Cortisol 2.75 μg/dl [reference value: 6.24–18.00 μg/dl]). Considering the transient hyperthyroidism during lenvatinib plus pembrolizumab administration (Fig. 3), we diagnosed hypothyroidism and hypopituitarism caused by lenvatinib plus pembrolizumab.

After the diagnosis of combined hypothyroidism and hypopituitarism, he received hydrocortisone (40 mg/day)
Fig. 1  Computed tomography images before and after lenvatinib plus pembrolizumab treatment. (orange arrow) a Metastatic tumor in segment 6 before treatment. b Metastatic tumor in segment 6 after treatment. c Metastatic tumor in segment 7 before treatment. d Metastatic tumor in segment 7 after treatment.

Fig. 2  Intraoperative views of laparoscopic partial hepatectomy and liver specimens. a Metastatic tumor in segment 6. b Metastatic tumor in segment 7. c Metastatic tumor in segment 6. d Metastatic tumor in segment 7.
first on the 9th postoperative day. Then, his fever, general fatigue, or any abnormality of fasting blood glucose level dissolved, and he was discharged on the 12th postoperative day. Following recovery of adrenal insufficiency, he received levothyroxine on the 14th postoperative day. He was alive without recurrence of gastric cancer and his laboratory data for thyroid and pituitary function remained stable while receiving hydrocortisone and levothyroxine for 2 years and 5 months.

**Discussion**

In this case report, we present a patient who underwent laparoscopic hepatectomy after receiving lenvatinib plus pembrolizumab and developed hypothyroidism and hypopituitarism after surgery. Although many clinical trials of ICI have been conducted [5–7], few studies of irAEs after surgery have been reported. Given that endocrine irAEs, such as hyperthyroidism, hypothyroidism, and hypopituitarism were observed in several trials even after the discontinuation of ICI [8], it is important to consider the possible occurrence of irAEs when patients undergo surgery after receiving ICI. Although there have been only one case report in which inflammatory process was developed in the left parietal lobe in the brain as irAEs of nivolumab and ipilimumab after craniotomy for resection of metastatic tumor from renal cancer [9], to the best of our knowledge, the present case report is the first one to report the development of endocrine irAEs in the immediate postoperative period.

The incidence of endocrine irAEs ranges from 5 to 20% [10–12]. The incidence of thyroid dysfunction, such as hypothyroidism and hyperthyroidism, is reported to range from 6 to 20%. Typically, thyroiditis caused by ICI triggers transient hyperthyroidism, followed by transient or permanent hypothyroidism in a median of 6–12 weeks [13, 14]. In the present case, transient hyperthyroidism was self-limiting and TSH levels slightly increased just before surgery (5.93 µIU/ml), although Free-T3/T4 levels were within the normal range at that time (2.36 pg/ml and 0.91 ng/dl for
Free-T3/T4, respectively). Although TSH was rising just before surgery, which might have been the early sign of irAE, we did not consider at that moment that it would provoke severe irAE immediately after surgery, because there had been no such reports. Now, our case indicates that even slightly elevated level of TSH needs attention before surgery. We consider that once the elevation of TSH is noticed, the initiation of thyroid hormone replacement therapy should be considered [15,16]. Hypopituitarism, which leads to pituitary–adrenal insufficiency caused by ICIs, is also frequently observed. The frequency of hypopituitarism induced by anti-PD-1 antibody and ipilimumab was reported as <1% and 10–17%, respectively [17]. Although the median time to hypopituitarism has been reported to range from 9 to 9.5 weeks [18,19], Otsubo et al. reported that late-onset irAEs might occur several months after ICI therapy [20]. Current guidelines require the replacement of deficient hormones to manage hypopituitarism [21]. Although high incidences of hypothyroidism and hypopituitarism have been reported with the co-therapy of nivolumab and ipilimumab, it is rare that hypothyroidism and hypopituitarism occur at the same time by the treatment of single ICI [22]. In the present case, corticosteroid replacement was started before levothyroxine replacement was initiated. Without corticosteroid replacement, levothyroxine replacement may unmask or exacerbate adrenal insufficiency and trigger an adrenal crisis, because levothyroxine may increase the clearance of cortisol [23,24]. In addition, we consider that surgical stress might exacerbate the development of hypopituitarism in this patient. Indeed, Hahner et al. reported that hypopituitarism was mainly precipitated by stressful events, such as surgery [25].

It is well known that patients who respond to ICI tend to develop irAEs [26]. In the present case, the patient responded effectively to ICI therapy before surgery. In case the surgery is performed for patients with a good response to anti-cancer drugs, it is necessary to pay special attention to irAEs in patients with ICI in the post-operative period by checking general appearance and laboratory testing.

Conclusions
We present a case of laparoscopic hepatectomy after receiving lenvatinib plus pembrolizumab and developed hypothyroidism and hypopituitarism after surgery. Regarding surgery after ICI therapy, it is important to recognize that irAEs might occur in the immediate post-operative period.

Abbreviations
ICIs: Immune checkpoint inhibitors; irAEs: Immune-related adverse events; CTCAE: Common Terminology Criteria for Adverse Events; TSH: Thyroid-stimulating hormone; ACTH: Adrenocorticotropic hormone.

Acknowledgements
We would like to thank Editage (www.editage.com) for English language editing.

Authors’ contributions
KS wrote the manuscript. SK and KS operated and managed the patient’s perioperative course. YN, AK, and KS managed lenvatinib plus pembrolizumab treatment. NG provided final approval of this manuscript. All authors have read and approved the final manuscript.

Funding
The authors received no funding for this study.

Availability of data and materials
All data supporting this study are included in this manuscript.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Because of the retrospective nature of the study and the absence of invasive interventions, patients’ personal written consents were waived.

Competing interests
There are no competing interests to declare.

Author details
1Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa-City, Chiba 277-8577, Japan.
2Department of Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa-City, Chiba 277-8577, Japan.
3Department of Gastric Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa-City, Chiba 277-8577, Japan.

Received: 21 October 2021   Accepted: 6 December 2021
Published online: 20 December 2021

References
1. Taylor M, Dutcus CE, Schmidt E, Bagulho T, Li D, Shumaker R, et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors. Ann Oncol. 2016;27:266–95.
2. Makker V, Rasco D, Vogelzang NJ, Borse MS, Cohn A, Lior J, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:711–8.
3. Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. Hoboken: Wiley-Blackwell; 2017.
4. Kawazoe A, Fukuoka S, Nakamura Y, Kuboki Y, Wakabayashi M, Nomura S, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1057–65.
5. Takeuchi S, et al. Early prediction of immune checkpoint inhibitor treatment efficacy in patients with untreated advanced non-small-cell lung cancer. University hospital Medical Information Network 2019 UMIN000037614. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042868.
6. Minami Y, Yamauchi N, Fuse N, et al. Phase II study of Nivolumab in patients with relapsed/refractory hematologic malignancies. University hospital Medical Information Network 2019 UMIN000033794. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037955.
7. Izumo T. Prospective study of anti-PD-L1 antibody therapy in advanced non-small cell lung cancer patients who previously treated with anti-PD-1 antibody. University hospital Medical Information Network 2018 UMIN000037867. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037867.

8. Torino F, Barnabei A, Paragialola RM, Marchetti P, Salvatori R, Corsello SM. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol. 2013;169:R153–64.

9. Patel AR, Connors S, Wardak Z, Brugarolas J, Patel TR. Inflammatory reaction secondary to immune checkpoint inhibitor therapy mimicking a post-operative brain abscess. World Neurosurg. 2019;129:354–8.

10. Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4:173–82.

11. Flesenu M, Hashim IA, Karaviti N, Melmed S, Murad MH, Salvatori R, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:3888–921.

12. Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015;21:749–55.

13. Morganstein DL, Lai Z, Spain L, Diem S, Levine D, Mace C, et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf). 2017;86:614–20.

14. McMullen B, Dhillon MS, Yong-Huy S. A rare case of thyroid storm. BMJ Case Rep. 2016. https://doi.org/10.1136/bcr-2016-214603.

15. Byun DJ, Wolchok JD, Rosenberg LM, Gitotra M. Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13:195–207.

16. Dadu R, Jozowiak C, Diab A. Managing adverse events with immune checkpoint agents. Cancer J. 2016;22:121–9.

17. Hasegawa S, Ikuse H, Nakao S, Shimada K, Mukai R, Tanaka M, et al. Analysis of immune-related adverse events caused by immune-checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Pharmacoepidemiol Drug Saf. 2020;29:1279–94.

18. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375–91.

19. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98:1361–75.

20. Otsubo K, Nakatomi K, Furukawa R, Ashida K, Yoneshima Y, Nakanishi Y, Okamoto I. Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab. Ann Oncol. 2017;28(12):3106–7.

21. Flesenu M, Hashim IA, Karaviti N, Melmed S, Murad M, Salvatori R, Samuels MH. Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:3888–921.

22. Hasegawa S, Ikuse H, Nakao S, et al. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Pharmacoepidemiol Drug Saf. 2020;29(10):1279–94.

23. Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99:4078–85.

24. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21:371–481.

25. Hahner S, Loeffler M, Bleicken B, Drechsler C, Milovanovic D, Fassnacht M, et al. Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur J Endocrinol. 2010;162:597–602.

26. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7:306.